Navigation Links
Nanogea Announces New Scientific Advisory Board Members
Date:10/9/2009

Nanogea Adds Drs. C. Thomas Caskey and Saul Tendler to its Scientific Advisory Board

Westlake Village, Calif. (PRWEB) October 9, 2009 -- Nanogea, a nano-biotech company focused on commercializing the industry's most sensitive single molecular detection platform, is pleased to announce today that Dr. C. Thomas Caskey and Dr. Saul Tendler have joined its scientific advisory board.

Dr. Caskey is a prominent medical geneticist and biomedical entrepreneur. Dr. Caskey presently serves as Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine, a research institute that seeks to investigate the cause of human diseases at the cellular and molecular levels using DNA and protein technologies to expose disease mechanisms. He is a former founding Director and CEO of Cogene Biotech Ventures, venture capital funds designed to support early-stage biotechnology and life science companies. Dr. Caskey is a former SVP for Res. at Merck and Trustee and President of the Merck Genome Res. Inst. as well as an Ex-Chief of Section of Medical Genetics and Professor of Medicine and Biochemistry, Baylor College of Medicine. He sits on the boards of Essex Woodlands Health Ventures, Luminex, Odyssey Thera, En Vivo, Metabolon, Genome Canada, LabCorp. of America, and Vice Chair of Genome Canada. Dr. Caskey is a member of the Academy of Medicine, Engineering and Science of Texas (President of TAMEST 2004-05), a member of the National Academy of Sciences, and the Institute of Medicine. Dr. Caskey received his medical doctorate from Duke University. He is Board certified in Internal Medicine, Clinical Genetics, Metabolic Diseases, and Molecular Diagnostics.

Dr. Saul Tendler is Pro-Vice-Chancellor, Professor of Biophysical Chemistry and Head of the School of Pharmacy, University of Nottingham. His expertise is in the field of biophysical chemistry, with a particular focus on analysis of biomolecular systems and their interactions. Dr. Tendler is a Fellow of the Royal Society of Chemistry, and was designated a Fellow of the Royal Pharmaceutical Society of Great Britain in 2000. Dr. Tendler received his Ph.D. from the University of Aston and his Bachelors of Science (First Class Honours) in Pharmacy at the University of Manchester.

"We are delighted to have a distinguished panel of advisors such as Drs. Caskey and Tendler," said Mr. David Sun, President and CEO of Nanogea, "Their extraordinary expertise and background will help guide Nanogea's research and development in the foreseeable future as we expedite our development effort to commercialize our first clinical application for CML (Chronic Myelogeous Leukemia) detection, based on our proprietary NanoCone™ chemistry and NE-AFM™ platform."

About Nanogea
Nanogea, a nano-biotech company located in Westlake Village California, is focused on commercializing the industry's most sensitive genomic and proteomic detection platform based on its innovative NanoCone™ chemistry and NanoCone Enabled Atomic Force Microscopy (NE-AFM™ ) technology. The Company is utilizing its technology to push the genetic and protein detection limit to the single molecular level, thus greatly improving the sensitivity and accuracy of disease diagnosis, prognosis, treatment, and monitoring as well as drug discovery research. To learn more about our pioneering technology, visit www.nanogea.com.

Nanogea Corporation
5716 Corsa Avenue, Suite 201
Westlake Village, CA 91362.
Phone: (818) 889-0538    Fax: (818) 889-0816
E-mail: mlowrey(at)nanogea(dot)com
Website: www.nanogea.com

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3017444.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors
2. IridoTech Announces IridoLab Self Service Kiosk
3. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
4. NCIIA Announces New Undergraduate Competition
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies
7. Verenium Announces Proposed Public Offering of Common Stock
8. Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
9. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
10. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
11. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... THOUSAND OAKS, Calif. , Dec. 2, 2016 ... AGN ) today announced the submission of a ... for ABP 215, a biosimilar candidate to Avastin ® ... biosimilar application submitted to the EMA. "The ... milestone as Amgen seeks to expand our oncology portfolio," said ...
(Date:12/2/2016)... -- Research and Markets has announced the addition ... Companies" to their offering. ... , , ... industries is anticipated. Nanotechnology will be applied at all stages ... diagnostic applications in clinical trials. Many of the assays based ...
(Date:12/2/2016)... , ... December 01, 2016 ... ... will share findings demonstrating the value of DNA microarray comparative genomic hybridization ... year’s San Antonio Breast Cancer Symposium. Using molecular test results from tumors ...
(Date:12/2/2016)... ... 01, 2016 , ... PhUSE will build on the huge ... Single Day Events (SDE) to organize a multiple-day US conference. The first annual ... of the pharmaceutical and life sciences industry will cover industry standards, data science, ...
Breaking Biology Technology:
(Date:11/29/2016)... VILNIUS, Lithuania , Nov. 29, 2016 ... high-precision biometric identification and object recognition technologies, ... kit (SDK) for fingerprint recognition solutions that ... extract a fingerprint template using less than ... used in compact devices that have limited ...
(Date:11/24/2016)... , Nov. 23, 2016 Cercacor today ... athletes and their trainers non-invasively measure hemoglobin, ... Pulse Rate, and Respiration Rate in approximately 30 seconds. ... users easy and immediate access to key data about ... of a training regimen. Hemoglobin carries ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
Breaking Biology News(10 mins):